BIO vs DHR
BIO: A multinational life science and clinical diagnostics company providing research tools, diagnostic test systems, and consumables to laboratories and biopharmaceutical manufacturers worldwide. DHR: Danaher is a diversified conglomerate providing scientific instruments, diagnostics, and industrial solutions across life sciences, environmental monitoring, product identification, and healthcare globally.
Side-by-side fundamentals
| Metric | BIO | DHR | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $305.96 | $179.14 | |
| Market cap as of 2026-07-23 | $8.2B | $125.9B | |
| P/E as of 2026-07-23 | 48.82 | 34.12 | DHR lower |
| PEG as of 2026-07-23 | n/a | 3.97 | |
| Net margin as of 2026-07-23 | +6.5% | +14.9% | DHR higher |
| Gross margin as of 2026-07-23 | +51.8% | +59.0% | DHR higher |
| Operating margin as of 2026-07-23 | +2.0% | +19.2% | DHR higher |
| ROE as of 2026-07-23 | +2.4% | +7.1% | DHR higher |
| ROA as of 2026-07-23 | +1.7% | +4.5% | DHR higher |
| Debt / equity as of 2026-07-23 | 0.18 | 0.35 | BIO lower |
| Revenue growth (YoY) as of 2026-07-23 | +1.9% | +4.0% | DHR higher |
| Revenue CAGR (3y) SEC XBRL | -2.7% | -2.7% | Tie |
| Dividend yield as of 2026-07-23 | n/a | +0.9% | |
| Beta as of 2026-07-23 | 1.06 | 0.78 | |
| 1-year return as of 2026-07-22 close | +24.6% | -5.7% | BIO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.